Cinoxacin demonstrated effective in vitro antimicrobial activity against the Enterobacteriaceae, but negligible activity against Pseudomonas aeruginosa and gram-positive cocci. The activity of cinoxacin was slightly greater than that of nalidixic acid.
A number of synthetic organic acids containing cinnoline ring structures have been investigated for antimicrobial activity (3, 8) . Of these compounds, cinoxacin (1-ethyl-1,4-dihydro-4,oxo-[1,3]dioxolo [4,5-g] cinnogine-3-carboxylic acid) was chosen for clinical and expanded in vitro investigation. Cinoxacin (Lilly compound 64715) possesses many characteristics similar to nalidixic acid and oxolinic acid. Preliminary in vitro bacterial susceptibility studies indicate a similar gram-negative antibacterial activity to that of nalidixic acid (2, 5, 7) .
This study presents in vitro broth dilution susceptibility data for cinoxacin against 2 5 Al of this dilution to each 100-,ul well; final inoculum concentration was 5 x 10'5 organisms/ml.
In the inoculum size studies, organisms were inoculated as above, using similar equipment and three inoculum concentrations, 107, 10', and 103 organisms/ml. MIC end points were defined as the lowest broth concentration totally inhibiting organism growth (clear well) after 15 to 18 h of incubation at 35 C. Determination of the MBC was performed by subculturing 1 MAl of both turbid and clear wells into Mueller-Hinton broth. The MBC was defined as the lowest subcultured broth concentration revealing no growth (clear well) after overnight incubation at 35 C. This represents a three-log minimum-kill (99.9%) end point.
RESULTS AND DISCUSSION
The cumulative percentage of gram-negative bacilli inhibited by increasing cinoxacin concentrations is shown in Table 1 . Among the 2,139 strains tested, Escherichia coli, Citrobacter diversus, Proteus morganii, and Proteus vulgaris exhibited the greatest susceptibility. Ten of the thirteen tabulated Enterobacteriaceae species showed greater than 90% inhibition of strains at 16 ,ug/ml. Only Proteus mirabilis, Proteus rettgeri, and Providencia species demonstrated a relative resistance to cinoxacin. All P. morganii and P. vulgaris strains were inhibited by 4 ug/ml in contrast to 67 and 0% for Proteus rettgeri and Providencia species, respectively. Only 12 of 210 pseudomonas isolates had MIC values of 64 jig/ml or less. However, 43 of the 57 non-Enterobacteriaceae, nonpseudomonas gram-negative isolates had MIC values of 64 Ag/ml or less.
The data in Table 2 confirm the poor cinoxacin antimicrobial activity against gram-positive organisms. Of note, however, was the 26 to 28% inhibitory response of staphylococcus isolates. Only 2 of 191 streptococcus strains had MIC values of 64 ,ug/ml or less.
The comparison of cinoxacin and nalidixic acid MICs and MBCs is shown in Table 3 . The six organism species tested represent six of the a Includes Pseudomonas maltophilia (6), P. stutzeri (3) , P. cepacia (2), and Pseudomonas species (2). b Includes Pasteurella multocida (4), Aeromonas hydrophilia (3), enteropathogenic E. coli (3), Shigella species (22), Salmonella enteritidis (7), and one strain each ofEF4, Ve type 2, Vd, 11K type 1, Achromobacter xylosoxidans, Flavobacterium species, and gram-negative bacillus NOS. Streptococcus, beta-hemolyticb. 4 Streptococcus, viridans group .8 13 a Includes S. faecium (5), S. durans (1), and S. bovis (1). b Includes S. agalacteae (1) and beta streptococcus not group A, B, or D (3). eight more frequently encountered urinary tract pathogens (Staphylococcus epidermidis and Enterobacter species not included). In direct comparison, cinoxacin was slightly more active than nalidixic acid against the group.
The effect of the inoculum size on the cinoxacin MIC results is shown in Table 4 . Slight increases in the mean MIC values were demonstrated for all tested species with increasing inoculum concentrations. However, four-to eightfold increase in MBCs was found for both cinoxacin and nalidixic acid with an inoculum size of 107 organisms/ml (not shown). At the highest concentration tested (64 ug/ml), 87% of the 1,621 urinary tract isolates were inhibited by cinoxacin. This concentration was considerably below the 250-to 500-,ug/ml concentration of drug easily reached in the urine 'on tisual dosages (6) . With a higher testing, range, the percentage of organisms inhibited may approach those of nitrofurantoin (94% inhibited at 128 ,g/ml) and trimethoprim/sulfamethoxazole (98% inhibited at 4/76 Ag/ml). If the grampositive urinary microbes were eliminated, the cinoxacin efficacy of 96% at 64 ,g/ml was comparable to that of the other two antimicrobial agents tested in parallel.
Cinoxacin appears to have definite advantages over nalidixic acid, including higher serum and urine concentrations, expanded Enterobacteriaceae antimicrobial activity, and a greater homogeneity of susceptible bacterial populations (8 (2) .
